US › Healthcare

Acurx Pharmaceuticals LLC (ACXP)

US · Healthcare · Biotechnology

$1.39+0.72%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-2.3M

EPS

$-0.53

EPS estimate

$-0.42

EPS came in at -0.53 against a street estimate of -0.42 — a miss of 26.2%.

Key statistics

Market cap

$6.0M

Forward P/E

0.0

P/B

0.74

Book value

$1.74

EPS (TTM)

$-2.44

52-week high

$8.34

52-week low

$1.31

50-day MA

$1.47

200-day MA

$2.35

Beta

-2.02

Analyst view

Analysts rate Acurx Pharmaceuticals LLC a buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $17.00.

Shareholding

Insiders

2.35%

Institutions

3.71%

Largest institutional holders

Fund	Stake
Jane Street Group LLC	0.98%
Vanguard Capital Management, LLC	0.56%
Geode Capital Management, LLC	0.45%
CAMBRIDGE Invest RESEARCH ADVISORS, INC.	0.36%
Vanguard Fiduciary Trust Co	0.29%
Prospect Financial Services Llc	0.25%
Morgan Stanley - Brokerage Accounts	0.12%
UBS Group AG	0.11%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Acurx Pharmaceuticals LLC — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.